KR950700241A - 신규한 아미딘 유도체, 이의 제조방법 및 LTB_4 길항작용을 하는 약제로서의 이의 용도(Novel amidine derivatives, their preparation and their use as medicaments with LTB_4 antagonistic effect) - Google Patents

신규한 아미딘 유도체, 이의 제조방법 및 LTB_4 길항작용을 하는 약제로서의 이의 용도(Novel amidine derivatives, their preparation and their use as medicaments with LTB_4 antagonistic effect)

Info

Publication number
KR950700241A
KR950700241A KR1019940702669A KR19940702669A KR950700241A KR 950700241 A KR950700241 A KR 950700241A KR 1019940702669 A KR1019940702669 A KR 1019940702669A KR 19940702669 A KR19940702669 A KR 19940702669A KR 950700241 A KR950700241 A KR 950700241A
Authority
KR
South Korea
Prior art keywords
alkyl
halogen
formula
compound
acyl
Prior art date
Application number
KR1019940702669A
Other languages
English (en)
Other versions
KR0163222B1 (ko
Inventor
안더스케비츠 랄프
슈롬 쿠르트
렌트 에른스트-옷토
함멜스바흐 프랑크
비르게 프란츠
퓌그너 아르민
Original Assignee
디터 라우딘, 루돌프 호프만
베링거 인겔하임 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4203201A external-priority patent/DE4203201A1/de
Priority claimed from DE4224289A external-priority patent/DE4224289A1/de
Priority claimed from DE4244241A external-priority patent/DE4244241A1/de
Application filed by 디터 라우딘, 루돌프 호프만, 베링거 인겔하임 카게 filed Critical 디터 라우딘, 루돌프 호프만
Publication of KR950700241A publication Critical patent/KR950700241A/ko
Application granted granted Critical
Publication of KR0163222B1 publication Critical patent/KR0163222B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 통상적인 방법으로 제조될 수 있고 통상적인 생약 제조로서 치료용으로 사용되는 다음 일반식(Ⅰ)의 화합물에 관한 것이다.

Description

신규한 아미딘 유도체, 이의 제조방법 및 LTB4길항작용을 하는 약제로서의 이의 용도(Novel amidine derivatives, their preparation and their use as medicaments with LTB4antagonistic effect)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 라세미체로서, 순수하거나 집중적인 형태를 이룬 거울상 이성체, 가능하게는 부분입체이성체의 쌍으로서, 시스- 또는 트랜스 형태로서, 및 유리 염기 또는 염, 바람직하게는 약리학적으로 허용되는 산과의 염으로서의 다음 일반식(Ⅰ)의 화합물.
    상기식에서, R1및 R2는 동일하거나 상이하며, CF3, 할로겐, R5, OR5, COR6, SR6, SOR6, S02R6, S02NR5R7또는 C(OH)R5R7이거나, 벤젠 환의 인접한 탄소 원자와 결합하여, 각각 C1-4알킬에 의해 치환될 수 있는 -CR8=CR9-CH=CH-, -CH=CR8-CR9=CH-, -CR8=CH-CR9=CH-, -0-CHR10-CH12-, 0-CH2-0-, -0-CH|2-CH2-0-, -(CH2)3-4, -NH-CO-0-, -NH-CO-CH2-0-, -CO-CH2-0- 또는 -CO-CH2CH2-0의 이중결합된 그룹을 나타낼 수 있고, R3은 할로겐, OH, CF3, R5, OR6, COR6, CONH5R7, CH2OH, CH2-0(C1-4-알킬), SR6, SOR6, SO2R6, S02NR5R7, NH-CO-(C1-4-알킬), NH-S02-(C1-4-알킬), NR5R7또는 C(OH)R5R7[여기서, R3이 R5와 동일한 경우, 치환체 R1및 R2중의 적어도 하나가 H가 아니라면 R5는 반드시 H이다]이거나, 1 내지 3개의 헤테로 원자를 갖는 일반식
    헤테로사이클릭 5원환[여기서, D, E 및 G는 동일하거나 상이하며, CH, N, C-(C1-4-알킬) 또는 C-페닐이고, L은 0 또는 S이다]이며, R4는 할로겐, NH2, NH-(C1-4-알킬); N(C1-4-알킬)2, OH 또는 C1-4-알콕시이고, R5는 H, C1-12-알킬 또는 페닐이거나, 할로겐, C1-4-알킬, C1-4-알콕시 또는 C2-5-아실에 의해 임의로 치환된 페닐이거나, 또는 페닐-(C1-4-알킬)이며, R6은 C1-12-알킬 또는 페닐이거나, 할로겐, C1-4-알킬, C1-4-알콕시 또는 C2-C5-아실에 의해 임의로 치환된 페닐이고, R7은 H 또는 C1-12-알킬이며, R8및 R9는 동일하거나 상이하고, H, OH, C1-4-알킬, C1-4-알콕시 또는 C2-5-아실이며, R10은 H 또는 C1-4-알킬이고, R11및 R12는 동일하거나 상이하며, H, OH, 할로겐, CF3, C1-4-알킬 또는 C1-4-알콕시이고, A는 그룹
    X1-A1-X2(Ⅱ)
    X2-A2-X3(Ⅲ)
    X4-A2-X2(Ⅳ)
    (CH2)1-2-NH-CO-(CH2)1-3-X2(Ⅴ)
    -CH=CH-A2-X2(Ⅵ)
    중의 하나이며, B는 CH=CH, CH=N, S 또는이고, A1은 C2-4-알킬렌, 시스- 또는 트랜스 -CH2-CH=CH-CH2,
    CH2-CC-CH2,
    또는이며, A는 C1-5-알킬렌이고, X1은 O, NH, S, SO, SO2, CO, CH2또는이며, X2는 O, NH, S 또는이고, X3은 NH-CO, CO-NH, SO2-NH 또는이며, X4는 NH-CO, CO-NH, NH-S02, S02-NH 또는 NH-CO-NH이다.
  2. 다음 일반식(Ⅰ')의 화합물.
    상기식에서, R1및 R2는 동일하거나 상이하며, R7, OR7, COR6또는 할로겐이거나, 벤젠 환의 인접한 탄소원자와 결합하여, -CR8=R9-CH=CH-, -CH=CR8-CR9=CH-, -0-CHR10-CH2- 또는 -CO-CH2-CH2-0-의 이중결합된 그룹을 나타낼 수 있고, R3은 할로겐, CF3, R7, OR7, C0-(C1-4-알킬), NH-CO-(C1-4-알킬), NHS02-(C1-4-알킬) 또는 N(R10)2[여기서, 치환체 R1및 R2중의 적어도 하나가 H가 아닌 경우, R7은 반드시 H이다]이거나, 일반식
    헤테로사이클릭 5원 환이며, R6및 R7은 위에서 정의한 바와 같고, A는 그룹(Ⅱ)이다.
  3. 제1항 또는 제2항에 있어서, R1/R2/R3이 C2-5-아실/H/H, C6H5CO/H/H, C1-4-알킬/OH/H, C2-5-아실/C1-4-알킬/H, C2-5-아실/OH/C1-4-알킬 또는 OH/C2-5-아실/C1-4-알킬인 화합물.
  4. 제1항 내지 제3항 중의 어느 한 항에 있어서, A가 0-(CH2)2-0, 0-(CH2)4-0 또는인 화합물.
  5. 제1항 내지 제4항 중의 어느 한 항에 있어서, 그룹(Ⅱ)가 아세틸페닐렌 화합물.
  6. 제1항 내지 제5항 중의 어느 한 항에 있어서, 그룹이인 화합물.
  7. 유리 염기 또는 산 부가염 형태인 다음 일반식의 화합물.
    상기식에서, a는 0 또는 1이고, b는 1 또는 2이며, R은 C1-4-알킬이고, 단 a가 0 또는 1이고 b가 1인 경우와 a가 1이고, b가 2인 경우에는, R이 수소일 수도 있다.
  8. 제7항에 있어서, 유리 염기로서 또는 산 부가염으로서, a가 0 또는 1이고 b가 1이거나 a가 0이고 b가 2인 화합물.
  9. 제8항에 있어서, 유리 염기로서 또는 산 부가염으로서, R이 H, CH3또는 C2H5이고 a가 0 또는 1이며, b가 1인 화합물.
  10. 제8항에 있어서, 유리 염기로서 또는 산 부가염으로서, a가 0이고 b가 2이며 R이 CH3인 화합물.
  11. 제1항 내지 제10항 중의 어느 한 항에 따른 화합물을 함유함을 특징으로 하는 약제학적 조성물.
  12. 염증성 및/또는 알레르기성 증상이 관련된 질환, 특히 천식, 궤양성 대장염 및 건선의 치료와 비스테로이드성 소염제에 의해 유도된 위장질환의 치료를 목적으로 하는 약제학적 조성물을 제조하기 위한, 제1항 내지 제10항 중의 어느 한 항에 따른 화합물의 용도.
  13. LTB4길항성 화합물이 사용될 수 있는 질환을 치료하기 위한, 제1항 내지 제10항 중의 어느 한 항에 따른 유효 복용량의 화합물의 용도.
  14. 염증성 및/또는 알레르기성 증상이 관련된 질환, 특히 천식, 궤양성 대장염 및 건선을 치료하고 비스테로이드성 소염제에 의해 유도된 위장 질환을 치료하기 위한, 제1항 내지 제10항 중의 어느 한 항에 따른 유효 복용량의 화합물의 용도.
  15. (a) 일반식(X)의 이미도에스테르를 암모니아와 반응시키거나, (b1) 일반식(XI)의 페놀 또는 티오페놀을 일반식(XII) 또는 (XIII)의 화합물과 반응시키거나, (b2) 일반식(XIV)의 페놀 또는 티오페놀을 일반식(XV), (XVI), (XVII) 또는 (XVIII)의 화합물과 반응시키거나, (c) 일반식(XIX)의 아미드옥심을 상응하는 아미딘이 형성되도록 환원시킴을 특징으로 하는, 제1항 내지 제10항 중의 어느 한 항에 따른 화합물의 제조방법.
    상기식에서, R1내지 R4, A, B, A1, A2, X2및 X3은 제1항에서 정의한 바와 같고, R은 바람직하게는 C1-6알킬 그룹 또는 벤질이며, Z는 OH 또는 SH이고, L은 이핵성 이탈 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702669A 1992-02-05 1993-01-14 아미딘 유도체, 이의 제조방법 및 이를 함유하는 ltd4 길항작용을 갖는 약제 KR0163222B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DEP4203201.6 1992-02-05
DE4203201A DE4203201A1 (de) 1992-02-05 1992-02-05 Neue amidinderivate, ihre herstellung und verwendung
DE4224289A DE4224289A1 (de) 1992-07-23 1992-07-23 Neue Amidinderivate, ihre Herstellung und Verwendung
DEP4224289.4 1992-07-23
DEP4244241.9 1992-12-24
DE4244241A DE4244241A1 (de) 1992-12-24 1992-12-24 Neue Verbindungen, ihre Herstellung und ihre Verwendung
PCT/EP1993/000070 WO1993016036A1 (de) 1992-02-05 1993-01-14 Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonischer wirkung

Publications (2)

Publication Number Publication Date
KR950700241A true KR950700241A (ko) 1995-01-16
KR0163222B1 KR0163222B1 (ko) 1999-01-15

Family

ID=27203364

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702669A KR0163222B1 (ko) 1992-02-05 1993-01-14 아미딘 유도체, 이의 제조방법 및 이를 함유하는 ltd4 길항작용을 갖는 약제

Country Status (29)

Country Link
US (3) US6037377A (ko)
EP (2) EP0902013B1 (ko)
JP (2) JP3487851B2 (ko)
KR (1) KR0163222B1 (ko)
AT (2) ATE180770T1 (ko)
AU (1) AU673343B2 (ko)
CA (2) CA2129526A1 (ko)
CZ (2) CZ287209B6 (ko)
DE (2) DE59309630D1 (ko)
DK (2) DK0902013T3 (ko)
ES (2) ES2132216T3 (ko)
FI (1) FI943618A (ko)
GR (1) GR3030468T3 (ko)
HR (1) HRP930102B1 (ko)
HU (1) HU216191B (ko)
IL (1) IL104589A0 (ko)
MX (1) MX9300630A (ko)
NO (1) NO301540B1 (ko)
NZ (1) NZ246593A (ko)
PL (2) PL173789B1 (ko)
PT (1) PT902013E (ko)
RU (1) RU2124002C1 (ko)
SG (1) SG44837A1 (ko)
SI (1) SI9300066B (ko)
SK (1) SK281016B6 (ko)
TW (1) TW232005B (ko)
UA (1) UA43318C2 (ko)
WO (1) WO1993016036A1 (ko)
YU (1) YU49038B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5488160A (en) * 1991-06-11 1996-01-30 Ciba-Geigy Corporation Amidino compounds, their manufacture and method of treatment
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
DE4309285A1 (de) * 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
DE4424714A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
CA2256309C (en) 1995-12-29 2006-08-15 3-Dimensional Pharmaceuticals, Inc. Amidino protease inhibitors
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
DE19637123A1 (de) * 1996-09-12 1998-03-19 Boehringer Ingelheim Kg Neue Pyranosidderivate
WO1998013347A1 (en) * 1996-09-26 1998-04-02 Novartis Ag Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
NZ528906A (en) 1997-05-14 2005-06-24 Atherogenics Inc Compounds and methods for the inhibition of the expression of VCAM-1
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
ID24720A (id) 1997-12-12 2000-08-03 Novartis Ag Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DE19948428A1 (de) * 1999-10-07 2001-04-12 Boehringer Ingelheim Pharma Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
FR2801053B1 (fr) * 1999-11-16 2004-06-25 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation et leur application a titre de medicaments
DE10052333A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Sulfooxybenzamide
US6528491B2 (en) * 2000-10-24 2003-03-04 Boehringer Ingelheim Pharma Kg Pyranoside derivatives
JP4334233B2 (ja) * 2001-04-11 2009-09-30 アセロジエニクス・インコーポレイテツド プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
US20030119901A1 (en) * 2001-07-14 2003-06-26 Boehringer Ingelheim Pharma Kg Pharmaceutical formulation containing an LTB4 antagonist
IL159493A0 (en) * 2001-07-14 2004-06-01 Boehringer Ingeiheim Pharma Gm Pharmaceutical formulation containing an ltb4 antagonist
WO2003017994A1 (en) * 2001-08-31 2003-03-06 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
GB2445920A (en) * 2007-01-25 2008-07-30 Mucokinetica Ltd Amidino compounds for treatment of respiratory disease
BRPI0809423A2 (pt) * 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc Usos e composições de derivados de probucol para o tratamento de diabetes
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
AU626033B2 (en) * 1988-10-25 1992-07-23 Government Of The United States Of America, As Represented By The Secretary Of The Army, The Methods for the treatment and prophylaxis of pneumocystis carinii pneumonia and other diseases and compounds and formulations for use in said methods
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
US5246965A (en) * 1991-06-11 1993-09-21 Ciba-Geigy Arylethers, their manufacture and methods of treatment
ATE125791T1 (de) * 1991-06-11 1995-08-15 Ciba Geigy Ag Amidino-verbindungen, ihre herstellung und verwendung als arzneimittel.
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors

Also Published As

Publication number Publication date
CA2427890A1 (en) 1993-08-19
US6037377A (en) 2000-03-14
ATE210634T1 (de) 2001-12-15
PL173781B1 (pl) 1998-04-30
EP0625138B1 (de) 1999-06-02
RU94041836A (ru) 1997-02-20
US6489365B1 (en) 2002-12-03
CZ287173B6 (cs) 2000-10-11
DK0902013T3 (da) 2002-03-25
AU673343B2 (en) 1996-11-07
HRP930102A2 (en) 1998-12-31
TW232005B (ko) 1994-10-11
EP0625138A1 (de) 1994-11-23
PL173789B1 (pl) 1998-04-30
RU2124002C1 (ru) 1998-12-27
HUT68419A (en) 1995-06-28
NO301540B1 (no) 1997-11-10
KR0163222B1 (ko) 1999-01-15
JPH07503718A (ja) 1995-04-20
US20030130232A1 (en) 2003-07-10
ATE180770T1 (de) 1999-06-15
ES2165122T3 (es) 2002-03-01
HU9402291D0 (en) 1994-10-28
AU3349793A (en) 1993-09-03
SK91494A3 (en) 1995-02-08
FI943618A0 (fi) 1994-08-04
HU216191B (hu) 1999-05-28
DE59309630D1 (de) 1999-07-08
YU49038B (sh) 2003-07-07
DK0625138T3 (da) 1999-11-15
SG44837A1 (en) 1997-12-19
JP3487851B2 (ja) 2004-01-19
UA43318C2 (uk) 2001-12-17
CZ287209B6 (en) 2000-10-11
ES2132216T3 (es) 1999-08-16
NO942903D0 (ko) 1994-08-04
CA2129526A1 (en) 1993-08-06
MX9300630A (es) 1993-09-01
YU6393A (sh) 1996-10-09
GR3030468T3 (en) 1999-10-29
EP0902013B1 (de) 2001-12-12
DE59310252D1 (de) 2002-01-24
JP2002322143A (ja) 2002-11-08
SI9300066B (sl) 2003-02-28
FI943618A (fi) 1994-08-04
NO942903L (no) 1994-10-03
CZ188694A3 (en) 1995-03-15
IL104589A0 (en) 1993-06-10
EP0902013A1 (de) 1999-03-17
SI9300066A (en) 1993-09-30
SK281016B6 (sk) 2000-10-09
HRP930102B1 (en) 2000-02-29
NZ246593A (en) 1997-07-27
WO1993016036A1 (de) 1993-08-19
PT902013E (pt) 2002-06-28

Similar Documents

Publication Publication Date Title
KR950700241A (ko) 신규한 아미딘 유도체, 이의 제조방법 및 LTB_4 길항작용을 하는 약제로서의 이의 용도(Novel amidine derivatives, their preparation and their use as medicaments with LTB_4 antagonistic effect)
DE69132167T2 (de) Kondensierte benzoxa-ringverbindung, deren herstellung sowie diese enthaltendes arzneimittel
KR900003170A (ko) 신규 화합물
GB2183234B (en) Pharmaceutically active sulphonamidoalkyl substituted phenoxyalkylcarboxylic acids and esters
NO172645C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater
TNSN91062A1 (fr) Derives nouveaux d'oxazolyle
ES2092844T3 (es) Uso de derivados de piridoxal para la preparacion de un medicamento para el tratamiento de cataratas.
ATE146453T1 (de) 1-aryloxy-3-alkylamino-2 propanol nitrat ester, ihre anwendung und korrespondierende pharmazeutische zusammensetzungen
ATE187968T1 (de) Antibiotische pyrrolidinylthiopenemderivate
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
SE8400629L (sv) Basiska oximetrar
ES8202826A1 (es) Procedimiento para la produccion de una 5,10-dihidroimidazo (2,1-b) quinazolina

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030826

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee